Association of Adiponectin with Peripheral Arterial Disease and Mortality in Nondiabetic Hemodialysis Patients: Long-term Follow-up Data of 7 Years

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2016 Dec 2

PMID 27904596

Citations 5

Authors

Yijun Zhou

Jiwei Zhang

Weiming Zhang

Zhaohui Ni

Affiliations

Soon will be listed here.

Abstract

Background: The relationships between adiponectin and clinical outcomes in hemodialysis (HD) patients remain highly controversial. Meanwhile, the association between adiponectin and the peripheral artery disease (PAD) has not been well studied in HD patients without diabetic mellitus.

Materials And Methods: The ankle-brachial index was measured in HD patients. Adiponectin levels in 105 HD patients were measured by Enzyme-Linked Immunosorbant Assay.

Results: 105 HD patients were enrolled; 14 (13%) patients had PAD. Using receiver-operating-characteristic (ROC) curve analysis for PAD, adiponectin (area under the curve [AUC] 0.935, 95% confidence interval [CI]: 0.848-0.981, < 0.001) showed significantly positive predictive value. During follow-up (mean 63 ± 30 months), 34 deaths (32%) occurred. Kaplan-Meier analysis found those patients lower median adiponectin had a significantly poor outcome ( < 0.05), and Cox analysis further confirmed that adiponectin was an independent predictor of overall mortality (hazard ratio [HR], 0.832, 95% CI: 0.696-0.995, < 0.05). The ROC curve of overall mortality showed that the AUC of adiponectin was 0.719 (95% CI: 0.586-0.813, < 0.05). In HD patients with PAD, the univariate analysis showed that adiponectin (HR, 0.649, 95% CI: 0.527-0.800, < 0.001) was also associated with overall mortality.

Conclusion: Decreasing levels of adiponectin were associated with a significant increase in the risk of PAD in HD patients without diabetic mellitus. Furthermore, as the results of our observation period (maximum of 7 years) showed, adiponectin was a predictor of all-cause mortality in HD patients.

Citing Articles

Circulating and Adipose Tissue Adiponectin Level and Outcomes in Incident Peritoneal Dialysis Patients.

Than W, Chan G, Kwan B, Lai K, Cheong-Kin Chan R, Teoh J Kidney Med. 2023; 5(3):100589.

PMID: 36793851 PMC: 9922972. DOI: 10.1016/j.xkme.2022.100589.

Comorbidity burden may explain adiponectin's paradox as a marker of increased mortality risk in hemodialysis patients.

Beberashvili I, Cohen-Cesla T, Khatib A, Hamad R, Azar A, Stav K Sci Rep. 2021; 11(1):9087.

PMID: 33907250 PMC: 8079690. DOI: 10.1038/s41598-021-88558-0.

Negative correlation of serum adiponectin level with peripheral artery occlusive disease in hemodialysis patients.

Lai Y, Lin Y, Wang C, Kuo C, Hsu B Tzu Chi Med J. 2020; 32(1):70-74.

PMID: 32110524 PMC: 7015003. DOI: 10.4103/tcmj.tcmj_19_19.

Evaluation of Agraz Consumption on Adipocytokines, Inflammation, and Oxidative Stress Markers in Women with Metabolic Syndrome.

Espinosa-Moncada J, Marin-Echeverri C, Galvis-Perez Y, Ciro-Gomez G, Aristizabal J, Blesso C Nutrients. 2018; 10(11).

PMID: 30400222 PMC: 6266490. DOI: 10.3390/nu10111639.

The Adiponectin Paradox for All-Cause and Cardiovascular Mortality.

Menzaghi C, Trischitta V Diabetes. 2017; 67(1):12-22.

PMID: 29263167 PMC: 6181068. DOI: 10.2337/dbi17-0016.

References

Tsigalou C, Chalikias G, Kantartzi K, Tziakas D, Kampouromiti G, Vargemezis V . Differential effect of baseline adiponectin on all-cause mortality in hemodialysis patients depending on initial body mass index. Long-term follow-up data of 4.5 years. J Ren Nutr. 2012; 23(1):45-56. DOI: 10.1053/j.jrn.2011.12.007. View

Selvin E, Erlinger T . Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004; 110(6):738-43. DOI: 10.1161/01.CIR.0000137913.26087.F0. View

Lash J, Go A, Appel L, He J, Ojo A, Rahman M . Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009; 4(8):1302-11. PMC: 2723966. DOI: 10.2215/CJN.00070109. View

Zoccali C, Mallamaci F, Tripepi G, Benedetto F, Cutrupi S, Parlongo S . Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2001; 13(1):134-141. DOI: 10.1681/ASN.V131134. View

Knudson J, Dick G, Tune J . Adipokines and coronary vasomotor dysfunction. Exp Biol Med (Maywood). 2007; 232(6):727-36. View

Li S, Shin H, Ding E, van Dam R . Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302(2):179-88. DOI: 10.1001/jama.2009.976. View

Liu J, Chen J, Lin S, Lin H, Ting I, Liang C . Comparing Survival between peritoneal dialysis and hemodialysis patients with subclinical peripheral artery disease: a 6-year follow-up. Int J Med Sci. 2013; 10(4):434-40. PMC: 3590604. DOI: 10.7150/ijms.5091. View

Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber M, Summer R . Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest. 2007; 117(2):375-86. PMC: 1770947. DOI: 10.1172/JCI29709. View

Diez J, Estrada P, Bajo M, Fernandez-Reyes M, Grande C, Peso G . High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol. 2009; 30(3):244-52. DOI: 10.1159/000221147. View

10.

Adamczak M, Wiecek A . The adipose tissue as an endocrine organ. Semin Nephrol. 2013; 33(1):2-13. DOI: 10.1016/j.semnephrol.2012.12.008. View

11.

Kanbay M, Afsar B, Gusbeth-Tatomir P, Covic A . Arterial stiffness in dialysis patients: where are we now?. Int Urol Nephrol. 2009; 42(3):741-52. DOI: 10.1007/s11255-009-9675-1. View

12.

Antoniades C, Antonopoulos A, Tousoulis D, Stefanadis C . Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009; 10(3):269-79. DOI: 10.1111/j.1467-789X.2009.00571.x. View

13.

Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui M, Laskar M . The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010; 55(9):898-903. DOI: 10.1016/j.jacc.2009.09.055. View

14.

Ono K, Tsuchida A, Kawai H, Matsuo H, Wakamatsu R, Maezawa A . Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003; 14(6):1591-8. DOI: 10.1097/01.asn.0000065547.98258.3d. View

15.

Rao M, Li L, Tighiouart H, Jaber B, Pereira B, Balakrishnan V . Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant. 2008; 23(8):2619-28. PMC: 2727293. DOI: 10.1093/ndt/gfn070. View

16.

Belch J, Topol E, Agnelli G, Bertrand M, Califf R, Clement D . Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163(8):884-92. DOI: 10.1001/archinte.163.8.884. View

17.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

18.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7(8):941-6. DOI: 10.1038/90984. View

19.

Rhee C, Nguyen D, Moradi H, Brunelli S, Dukkipati R, Jing J . Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2015; 66(2):313-21. PMC: 4516594. DOI: 10.1053/j.ajkd.2015.02.325. View

20.

Wilson A, Kimura E, Harada R, Nair N, Narasimhan B, Meng X . Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007; 116(12):1396-403. DOI: 10.1161/CIRCULATIONAHA.106.683722. View